Strides Fast-Tracks China Entry With Joint Venture
India’s Strides has announced its entry into China through a joint-venture with one of the country’s leading pharmaceutical firms, Sihuan, at the same time as reporting first-quarter EBITDA that soared by 155%.
You may also be interested in...
Strides Pharma Science has acquired a majority stake in Swiss generics firm Fairmed Healthcare in a move to bolster its presence in central Europe. The acquisition marks the latest in a string of transactions by the Indian firm.
India's Strides has bought a Florida soft-gel capsule manufacturing plant for $500,000 and plans to pump in up to $10m in investment to build capacity and add dosage formats.
Following the formation of Australia’s Arrotex through the merger of Apotex Australia and former Strides unit Arrow Pharmaceuticals, CEO Dennis Bastas sets out the firm’s priorities as a central player in the Australian market, as well as longer-term plans including potential future deals and reaching beyond Australia and into south-east Asia, in an exclusive interview with Generics Bulletin.